Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Gabriela Hobbs, MD, on Deciding on Which TKI to Choose for Treatment-Free Remission

Posted: Tuesday, July 30, 2019

Gabriela Hobbs, MD, of Massachusetts General Hospital Cancer Center, discusses the factors associated with a higher risk of treatment-free remission failure in patients with CML who are treated with tyrosine kinase inhibitors.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.